Burgess DJ, Wright JC. An introduction to long acting injections and implants. In: In Burgess DJ, Wright JC, editors. long acting injections and implants. Springer; 2012. p. 1–9.
Kipp JE. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int J Pharm. 2004;284:109–22.
Article CAS PubMed Google Scholar
Rhee YS, Park CW, Deluca PP, Mansour HM. Sustained-release injectable drug delivery: a review of current and future systems. PharmTechnol. 2010;s6:8–13.
Maresova P, Javanmardi E, Barakovic S, BarakovicHusic J, Tomsone S, Krejcar O, Kuca K. Consequences of chronic diseases and other limitations associated with old age - a scoping review. BMC Public Health. 2019;19:1431.
Article PubMed PubMed Central Google Scholar
Brissos S, Veguilla MR, Taylor D, Balanzá-Martinez V. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol. 2014;4:198–219.
Article CAS PubMed PubMed Central Google Scholar
Remenar JF. Making the leap from daily oral dosing to long-acting injectables: lessons from the antipsychotics. Mol Pharm. 2014;11:1739–49.
Article CAS PubMed Google Scholar
Rubio JM, Schoretsanitis G, John M, Tiihonen J, Taipale H, Guinart D, Malhotra AK, Correll CU, Kane JM. Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis. Lancet Psychiatry. 2020;7:749–61.
Morris MT, Tarpada SP. Long-acting injectable paliperidone palmitate: A review of efficacy and safety. Psychopharmacol Bull. 2017;47:42–52.
PubMed PubMed Central Google Scholar
Owen A, Rannard S. Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy. Adv Drug Deliv Rev. 2016;103:144–56.
Article CAS PubMed PubMed Central Google Scholar
Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov. 2004;3:785–96.
Article CAS PubMed Google Scholar
Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Therapeut. 2001;23:1296–310.
Coleman CI, Limone B, Sobieraj DM, Lee S, Roberts MS, Kaur R, Alam T. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012;18:527–39.
Coleman CI, Roberts MS, Sobieraj DM, Lee S, Alam T, Kaur R. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin. 2012;28:669–80.
Article CAS PubMed Google Scholar
Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009;15:e22-33.
Leenen FH, Wilson TW, Bolli P, Larochelle P, Myers M, Handa SP, Boileau G, Tanner J. Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoring. Can J Cardiol. 1997;13:914–20.
Eberlin M, Otto G, Krämer I. Increased medication compliance of liver transplant patients switched from a twice-daily to a once-daily tacrolimus-based immunosuppressive regimen. Transplant Proc. 2013;45:2314–20.
Article CAS PubMed Google Scholar
Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55:886–91.
Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006;67:453–60.
Sajatovic M, Levin J, Ramirez LF, Hahn DY, Tatsuoka C, Bialko CS, Cassidy KA, Fuentes-Casiano E, Williams TD. Prospective trial of customized adherence enhancement plus long-acting injectable antipsychotic medication in homeless or recently homeless individuals with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2013;74:1249–55.
Article PubMed PubMed Central Google Scholar
Morrissette DA, Stahl SM. Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment. CNS Spectr. 2012;17(Suppl 1):10–21.
Okoli CTC, Kappi A, Wang T, Makowski A, Cooley AT. The effect of long-acting injectable antipsychotic medications compared with oral antipsychotic medications among people with schizophrenia: A systematic review and meta-analysis. Int J Ment Health Nurs. 2022;31:469–535.
Hirsch SR, Gaind R, Rohde PD, Stevens BC, Wing JK. Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry. Br Med J. 1973;1:633–7.
Article CAS PubMed PubMed Central Google Scholar
Kaunitz AM. Injectable long-acting contraceptives. Clin Obstet Gynecol. 2001;44:73–91.
Article CAS PubMed Google Scholar
Swindells S, Siccardi M, Barrett SE, Olsen DB, Grobler JA, Podany AT, Nuermberger E, Kim P, Barry CE, Owen A, Hazuda D, Flexner C. Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges. Int J Tuberc Lung Dis. 2018;22:125–32.
Article CAS PubMed Google Scholar
FDA. 2023; https://www.fda.gov/drugs/human-immunodeficiency-virus-hiv/fda-approves-cabenuva-and-vocabria-treatment-hiv-1-infection. accessed 13-Feb-2023.
Giliad. 2023; https://www.gilead.com/news-and-press/press-room/press-releases/2021/3/gilead-and-merck-announce-agreement-to-jointly-develop-and-commercialize-longacting-investigational-treatment-combinations-of-lenacapavir-and-islatr. accessed 13-Feb-2023.
Liversidge GG, Cundy KC, Bishop JF, Czekai DA. Surface Modified Drug Nanoparticles. United States Patent. 1992;5:145684.
Shi J, Wang D, Tian Y, Wang Z, Gao J, Liu N, Gao X, Zheng A, Zhang H, Xiang M. Comparison of paliperidone palmitate from different crystallization processes and effect on formulations in vitro and in vivo. Pharmaceutics. 2022;14:1094.
Article CAS PubMed PubMed Central Google Scholar
Kalepu S, Nekkanti V. Insoluble drug delivery strategies: review of recent advances and business prospects. Acta Pharm Sin B. 2015;5:442–53.
Article PubMed PubMed Central Google Scholar
Wu L, Zhang J, Watanabe W. Physical and chemical stability of drug nanoparticles. Adv Drug Deliv Rev. 2011;63:456–69.
Article CAS PubMed Google Scholar
Kesisoglou F, Panmai S, Wu Y. Nanosizing–oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev. 2007;59:631–44.
Article CAS PubMed Google Scholar
Malamatari M, Taylor KMG, Malamataris S, Douroumis D, Kachrimanis K. Pharmaceutical nanocrystals: production by wet milling and applications. Drug Discov Today. 2018;23:534–47.
Article CAS PubMed Google Scholar
Li M, Azad M, Davé R, Bilgili E. Nanomilling of Drugs for Bioavailability Enhancement: A Holistic Formulation-Process Perspective. Pharmaceutics. 2016;8:17.
Article PubMed PubMed Central Google Scholar
Verma S, Kumar S, Gokhale R, Burgess DJ. Physical stability of nanosuspensions: investigation of the role of stabilizers on Ostwald ripening. Int J Pharm. 2011;406:145–52.
Article CAS PubMed Google Scholar
Thanh NT, Maclean N, Mahiddine S. Mechanisms of nucleation and growth of nanoparticles in solution. Chem Rev. 2014;114:7610–30.
Article CAS PubMed Google Scholar
Nyqvist H, Wadsten T. Structure-related variation in epimer ratio and solvent content of bacampicillin hydrochloride. Acta Pharm Suec. 1985;22:215–28.
De Cleyn E, Holm R, Van den Mooter G. Shedding a light on the physical stability of suspensions micronised with intensified vibratory milling; A trend observed with decreasing particle size as a function of time. Int J Pharm. 2021;603:120687.
Joshi V, Dwivedi S, Ward GH. Increase in the specific surface area of budesonide during storage postmicronization. Pharm Res. 2002;19:7–12.
Article CAS PubMed Google Scholar
Lee RW, Shaw JM, McShane J, Wood RW, Shenoy DB. Particle size reduction. In: Water-insoluble drug formulations, Liu R (editor), Interpharm Press, 2008, Second Edition, chapter 17, pp. 467–99.
Kesteleyn B, Amssoms K, Schepens W, Hache G, Verschueren W, Van De Vreken W, Rombauts K, Meurs G, Sterkens P, Stoops B, Baert L, Austin N, Wegner J, Masungi C, Dierynck I, Lundgren S, Jönsson D, Parkes K, Kalayanov G, Wallberg H, Rosenquist A, Samuelsson B, Van Emelen K, Thuring JW. Design and synthesis of HIV-1 protease inhibitors for a long-acting injectable drug application. Bioorg Med Chem Lett. 2013;23:310–7.
Article CAS PubMed Google Scholar
Netzsch. 2022. (https://grinding.netzsch.com/en/pharma-cosmetics/wet-grinding), accessed 10-Nov-2022.
WAB. 2022. (https://www.wab-group.com/en/grinding-dispersing/agitator-bead-mills/) , accessed 10-Nov-2022.
留言 (0)